 MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that three abstracts have been accepted for presentation at the 62nd American Society of Hematology ASH Annual Meeting and Exposition, which will be held virtually from December 5-8, 2020. The presentations will focus on the companys anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02. In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood. 